Evommune shares tumble 13% after-hours after eczema pill trial fails
Evommune (EVMN) shares fell 13% after-hours Tuesday after the company said its experimental eczema pill failed a mid-stage study and will not move forward in that disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.